Loading...
Loading...
ANEB| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 2,864.0K |
| Operating I/L | -2,864.0K |
| Other Income/Expense | 66.1K |
| Interest Income | 79.2K |
| Pretax | -2,798.0K |
| Income Tax Expense | -66.1K |
| Net Income/Loss | -2,731.9K |
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company specializing in developing and commercializing treatments for acute cannabinoid intoxication and substance addiction. The company's primary focus is on its lead product candidate, ANEB-001, a small molecule cannabinoid receptor antagonist designed to address cannabinoid intoxication and overdose.
